Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1998-08-20
2000-09-26
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514544, 514569, A61K 3119, A61K 3122
Patent
active
061243582
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to a new stable pharmaceutical composition which can be used in human and veterinary therapy, and more particularly a new galenic form adapted to rhein and to diacetylrhein (diacerhein), substantially improving the bioavailability of the active ingredient.
BACKGROUND OF THE INVENTION
Rhein, or 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid, and diacerhein, its diacetylated derivative, that is to say 4,5-bis(acetyloxy)-9,10-dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarbo xylic acid, are described in numerous scientific publications as well as in patent FR-A-2,508,798. Diacerhein is well known as a medicament having antiarthritic activity, and is used in particular in the treatment of osteoarthritis. However, rhein and diacerhein have the disadvantage of being practically insoluble in water and in alcohols. Furthermore, diacerhein may be administered by the oral route, but it is not completely absorbed by the digestive tract, and this incomplete absorption could cause undesirable side effects, for example laxative effects. Moreover, the administration of rhein is thought to cause even more problems than that of diacerhein.
To overcome these difficulties, various derivatives as well as pharmaceutical compositions and specific galenic forms have been proposed in the literature. For example, patent EP-A-243,968 describes a water-soluble potassium salt of diacerhein which can be used in the preparation of compositions for parenteral administration.
It is known, moreover, that the solubilization and/or wettability of a substance can be improved by treatment by means of a surfactant, which generally has the effect of promoting bioavailability of the active ingredient. It is also known that the grinding of insoluble active ingredients in the presence of certain water-soluble polymers improves the solubility and bioavailability of the product (Yamamoto et al., J. Pharm. Sci. (1976) 65, p. 1484-88).
The grinding of the substances used in therapy can be carried out in ball or hammer mills of the customary type. The procedure can also be carried out by micronization in gaseous jet micronizers which have the advantage of not heating the substances to be micronized. The micronization technique has been used to develop a pharmaceutical composition based on bioavailable and orally administerable progesterone whose bioavailability is double that of the crystalline form previously known.
Patent EP-A-330,532 describes the comicronization of fenofibrate in the presence of sodium lauryl sulfate. On the other hand, M. Otsuda et al. (J.P.S. 84 (1995) p. 1434-37) have studied the micronization of phenitoin in the presence of a surfactant, and they have shown that the solubility of phenitoin is not improved in the case of comicronization with a surfactant such as sodium lauryl sulfate or a sucrose ester of stearic acid, whereas it is multiplied by 30 compared with the mixture of the powders, in the case of a cogrinding with sodium deoxycholate.
Moreover, even if the micronization or the grinding of a substance in the presence of a surfactant or of a sugar can increase its solubility, these parameters are not always adequate. For example, the bioavailability of micronized progesterone is not adequate and should be improved, for example by dispersion in carnauba wax. Such a technique is described in application WO-89,02742.
Thus, it appears that the properties of a substance treated by micronization or grinding, in particular its solubility and its bioavailability, are not predictable, it being possible to obtain contradictory results. Furthermore, an identical galenic formulation can provide good results with a substance and give the opposite result with another substance.
SUMMARY OF THE INVENTION
The subject of the present invention is a new stable pharmaceutical composition based on diacerhein for administration by the oral, rectal or cutaneous (percutaneous or transdermal) route, having improved bioavailability, and more particularly intended for th
REFERENCES:
patent: 4244968 (1981-01-01), Friedmann
patent: 4344934 (1982-08-01), Martin et al.
patent: 4895726 (1990-01-01), Curtet et al.
patent: 5393898 (1995-02-01), Careasona et al.
patent: 5652265 (1997-07-01), Vittori et al.
patent: 5856358 (1999-01-01), Bennetti et al.
Journal of Pharmaceutical Sciences, vol. 84, No. 12, Dec. 1995, pp. 1434-1437, "Effect of Cogrinding with Various Kinds of Surfactants on the Dissolution Behavior of Phenytoin".
Journal of Pharmaceutical Sciences, vol. 65, No. 10, Oct. 1976, pp. 1484-1488, "Dissolution Behavior and Bioavailability of Pheytoin froma Ground Mixture with Microcrystalline Cellulose".
Estanove Cyril
Prudhomme Alain
Mazal Pharmaceutique (SARL)
Reamer James H.
LandOfFree
Pharmaceutical composition containing rhein or diacerhein with i does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition containing rhein or diacerhein with i, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition containing rhein or diacerhein with i will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100772